- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Pwynt Penodol mewn Amser (31/12/2020)
- Gwreiddiol (a wnaed Fel)
Point in time view as at 31/12/2020.
There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Plant Protection Products (Fees and Charges) Regulations 2011. Any changes that have already been made by the team appear in the content and are referenced with annotations.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
Regulation 4(1)
Textual Amendments
F1Sch. 1 substituted (6.4.2016) by The Plant Protection Products (Fees and Charges) (Amendment) Regulations 2016 (S.I. 2016/254), regs. 1, 2(2)
1. Fees for product-related applications [F2to a United Kingdom competent authority] are in accordance with the following table, and each item is charged cumulatively.
Item | Chargeable item | Fee(£) | ||||
---|---|---|---|---|---|---|
1 | Administrative research and development application(1) | 52 | ||||
2 | Extension of use application including administration, co-ordination and technical consideration | 1,768 | ||||
3 | Preliminary consideration of application type listed in items 4, 5, 7,12 or 13 to determine whether the application can proceed further | 229 | ||||
4 | Administrative application(2)F3... for a new product or change to an existing product— | |||||
4a | one product | 156 | ||||
4b | each additional product(4) | 52 | ||||
5 | F4. . . | |||||
5a | F4. . . | F4. . . | ||||
5b | F4. . . | F4. . . | ||||
6 | Evaluation of a label in any application | 208 | ||||
7 | Co-ordination of standard technical stream applications (7)(8) | 1,872 | ||||
8 | Evaluation of simple reasoned cases in each of the following specialist areas— | |||||
8a | chemistry(9) | 416 | ||||
8b | toxicology(10) | 416 | ||||
8c | operator exposure(11) | 416 | ||||
8d | residues and consumer exposure(12) | 416 | ||||
8e | fate and behaviour in the environment(13) | 416 | ||||
8f | ecotoxicology(14) | 416 | ||||
8g | efficacy(15) | 416 | ||||
9 | Evaluation of data, modelling and detailed scientific cases in each of the following specialist areas— | |||||
9a | chemistry(9) | 780 | ||||
9b | toxicology(10) | 780 | ||||
9c | operator exposure(11) | 780 | ||||
9d | residues and consumer exposure(12) | 780 | ||||
9e | fate and behaviour in the environment(13) | 1,872 | ||||
9f | ecotoxicology(14) | 1,872 | ||||
9g | efficacy(15) | 1,872 | ||||
10 | Withdrawal of an application for a product specified in items 2, 4, 5, 7, 12 or 13 before any work other than preliminary consideration has been done | 104 | ||||
11 | Pre-submission meetings [F5to discuss potential product applications] (16) | 5,200 | ||||
12 | F6. . . | |||||
F6. . . | F6. . . | |||||
F6. . . | F6. . . | |||||
13 | Commenting on draft study protocols(18) | 416 |
Notes
(1) Application for authorisation under Regulation 1107/2009 not involving evaluation of technical information or data.
(2) Application for authorisation under Regulation 1107/2009 involving no technical consideration.
F7(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(4) Where the application relates to a number of different products, this charge applies to each additional product.
F7(5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F7(6) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(7) “Standard technical stream applications” are all applications other than [F8items 1-4, 10 and 11].
(8) The co-ordination of applications for new products or a change to an existing product.
(9) Chemistry covers assessment of the technical specification of the active substance, safeners and synergists in the product and the physico-chemical properties of the product.
(10) Toxicology covers assessment of the mammalian metabolism and toxicology of the active substance, safeners and synergists in the product and determination of the types of hazard to which the product can give rise.
(11) Operator exposure additionally covers exposure of other persons resulting from the product use.
(12) Consumer exposure covers exposure of consumers resulting from consumption of produce from treated crops, treated produce or products derived from either, including products from animals to which any such matter has been fed.
(13) Fate and behaviour in the environment covers the potential environmental exposure from product use, including the identity and quantity of the active substance, metabolites, degradation products and reaction products, safeners and synergists which may be available in the soil, water or air and are of toxicological or environmental significance.
(14) Ecotoxicology covers the assessment of the potential impact on non-target species likely to be at risk from exposure to the product, including the active substance, and toxicologically or environmentally significant metabolites, degradation products and reaction products, safeners and synergists.
(15) Efficacy covers the assessment of whether a product consistently controls the target pest and whether the product adversely affects the treated crops, following crops or treated produce.
(16) Pre-submission meetings may be held at the request of the applicant prior to the submission of an application F9....
F10(17) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(18) The fee is equivalent to a specialist case fee and relates to requests from applicants for [F11a United Kingdom competent authority] to comment on the study design in advance of the data being generated and an application being submitted. For particularly complex protocols requiring significant specialist input it may be necessary to charge a data module fee in the relevant specialist area.
Textual Amendments
F2Words in Sch. 1 para. 1 inserted (31.12.2020) by S.I. 2019/720, Sch. 1 para. 14(2)(a) (as inserted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 10(2)(b))
F3Word in Sch. 1 para. 1 Table Item 4 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(b)(i) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
F4Sch. 1 para. 1 Table Item 5-5b omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(b)(ii) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
F5Words in Sch. 1 para. 1 Table Item 11 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(b)(iii) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
F6Words in Sch. 1 para. 1 Table Item 12 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(b)(iv) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
F7Sch. 1 para. 1 Notes 3, 5, 6 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(c)(i) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
F8Words in Sch. 1 para. 1 Note 7 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(c)(ii) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
F9Words in Sch. 1 para. 1 Note 16 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(c)(iii) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
F10Sch. 1 para. 1 Note 17 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(c)(iv) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
F11Words in Sch. 1 para. 1 Note 18 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(2)(c)(v) (as amended by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(2)(a)); 2020 c. 1, Sch. 5 para. 1(1)
[F121A. Fees for parallel trade applications to the Northern Ireland competent authority are in accordance with the following table, and each item is charged cumulatively.
Item | Chargeable item | Fee(£) |
---|---|---|
(1) Application for a parallel trade permit for other than personal use. | ||
(2) Verification that the product to be traded is identical to a product authorised in accordance with Regulation 1107/2009.] | ||
1 | Preliminary consideration of an application to determine whether the application can proceed further | 229 |
2 | Parallel trade applications— | |
(a) co-ordination of application for a new product or change to an existing product involving parallel trade(1) | 728 | |
(b) parallel trade verification(2) | 208 | |
(c) parallel trade permit for personal use | 156 |
Textual Amendments
F12Sch. 1 para. 1A inserted (31.12.2020) by S.I. 2019/720, Sch. 01 para. 014(02A) (as inserted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 10(3))
2. The fees [F14chargeable by a Great Britain competent authority] for evaluation for approval, or renewal of approval, under Regulation 1107/2009 of an active substance, safener [F15, synergist or basic substance], are in accordance with the following table.
Item | Application | Fee(£) | |||||
---|---|---|---|---|---|---|---|
Where an active substance, safener [F16, synergist or basic substance] is neither a biocontrol agent nor a pheromone | |||||||
1 | Preliminary evaluation(1) of the admissibility of an application | 5,200 | |||||
2 | F17. . . | F17. . . | |||||
3 | [F18Co-ordination of scientific advice and public consultation and finalising the draft assessment report] | 36,400 | |||||
4 | Evaluation of a full data package(3) | 114,400 | |||||
5 | Evaluation of a partial data package(4): | ||||||
Band 1 | 7,800 | ||||||
Band 2 | 15,600 | ||||||
Band 3 | 31,200 | ||||||
Band 4 | 52,000 | ||||||
Band 5 | 72,800 | ||||||
Band 6 | 93,600 | ||||||
Band 7 | 114,400 | ||||||
Where an active substance is a biocontrol agent | |||||||
6 | Evaluation of a full data package (3) | 23,400 | |||||
7 | [F19Co-ordination of scientific advice and public consultation, and finalising the draft assessment report] | 7,800 | |||||
8 | Evaluation of a partial data package(4): | ||||||
Band 1 | 5,720 | ||||||
Band 2 | 11,700 | ||||||
Band 3 | 17,680 | ||||||
Band 4 | 23,400 | ||||||
Where an active substance is a pheromone | |||||||
9 | Evaluation of a full data package(3) | 13,520 | |||||
10 | [F19Co-ordination of scientific advice and public consultation, and finalising the draft assessment report] | 7,800 | |||||
11 | Evaluation of a partial data package:(4) | ||||||
Band 1 | 3,380 | ||||||
Band 2 | 6,760 | ||||||
Band 3 | 10,140 | ||||||
Band 4 | 13,520 | ||||||
For all evaluations | |||||||
12 | Meeting before the submission of an application in support of a new active substance, safener, synergist, [F20basic substance,] biocontrol agent or pheromone | 5,200 |
Notes
(1) The initial evaluation carried out in order to notify the applicant whether his or her application can proceed further.
F21(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(3) [F22In relation to active substances, safeners or synergists,] a full data package comprises the complete dossier (the information referred to in paragraphs 1 and 2 of Article 8 of Regulation 1107/2009) to support one or more representative use of one product. [F23In relation to basic substances, a full data package comprises the complete dossier (the information referred to in Article 23(3) of Regulation 1107/2009) to support one or more uses of the basic substance.] Where a data package also contains a large number of extra study reports submitted to refine risk assessments, to characterise metabolites or to support additional uses of the product [F24or basic substance], these studies will be treated as an additional partial data package. See also note (4).
(4) The size of a partial data package is banded as a proportion of a full data package. The proportion is estimated on the basis of the amount of time required to evaluate the data and to conduct the necessary risk assessments. Applicants will be notified of the appropriate Band prior to an evaluation taking place. Partial data packages include one or more of the following—
(a)additional data over and above a ‘standard’ core dossier for example situations where there are significantly more metabolites, or very large novel studies to be evaluated;
(b)additional study submissions during evaluation required to clarify the initial dossier;
F25(c). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(d)[F26 in relation to active substances, safeners or synergists,] data to support the extension of the approval of an active substance, safener or synergist under Regulation 1107/2009 once the initial approval period has expired or to change the conditions of approval during the approval period;
F27(e). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(f)[F28in relation to active substances, safeners or synergists,] large data packages in one or more areas of the risk assessment that have been submitted in support of product related applications (e.g. re-registration and new product applications under Regulation 1107/2009) that significantly exceed the size for which the standard fees specified in the product-related application fees table (paragraph 1, items 9a-g above) are payable.
(g)[F28in relation to active substances, safeners or synergists,] additional studies submitted to support an adverse data review.
[F29(h)in relation to basic substances, resubmissions (for example where the previous application for approval under Regulation 1107/2009 has been unsuccessful and a new application is made in an attempt to address all the concerns raised from that earlier submission);
(i)in relation to basic substances, data to support a change to the conditions of approval of the basic substance.]
[F30The evaluation of scientific peer reviewed open literature on the active substance or basic substance and its relevant metabolites will be treated as a partial data package.]
Textual Amendments
F13Words in Sch. 1 para. 2 heading substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(a); 2020 c. 1, Sch. 5 para. 1(1)
F14Words in Sch. 1 para. 2 inserted (31.12.2020) by S.I. 2019/720, Sch. 1 para. 14(3)(b)(i) (as substituted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 10(4))
F15Words in Sch. 1 para. 2 substituted (31.12.2020) by S.I. 2019/720, Sch. 1 para. 14(3)(b)(ii) (as substituted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 10(4))
F16Words in Sch. 1 para. 2 Table heading substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(c)(i); 2020 c. 1, Sch. 5 para. 1(1)
F17Sch. 1 para. 2 Table Item 2 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(c)(ii); 2020 c. 1, Sch. 5 para. 1(1)
F18Words in Sch. 1 para. 2 Table Item 3 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(c)(iii); 2020 c. 1, Sch. 5 para. 1(1)
F19Words in Sch. 1 para. 2 Table Item 7, 10 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(c)(iv); 2020 c. 1, Sch. 5 para. 1(1)
F20Words in Sch. 1 para. 2 Table Item 12 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(c)(v); 2020 c. 1, Sch. 5 para. 1(1)
F21Sch. 1 para. 2 Note 2 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(d)(i); 2020 c. 1, Sch. 5 para. 1(1)
F22Words in Sch. 1 para. 2 Note 3 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(d)(ii)(aa); 2020 c. 1, Sch. 5 para. 1(1)
F23Words in Sch. 1 para. 2 Note 3 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(d)(ii)(bb); 2020 c. 1, Sch. 5 para. 1(1)
F24Words in Sch. 1 para. 2 Note 3 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(d)(ii)(cc); 2020 c. 1, Sch. 5 para. 1(1)
F25Sch. 1 para. 2 Note 4(c) omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(d)(iii)(aa); 2020 c. 1, Sch. 5 para. 1(1)
F26Words in Sch. 1 para. 2 Note 4(d) inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(d)(iii)(bb); 2020 c. 1, Sch. 5 para. 1(1)
F27Sch. 1 para. 2 Note 4(e) omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(d)(iii)(cc); 2020 c. 1, Sch. 5 para. 1(1)
F28Words in Sch. 1 para. 2 Note 4(f)(g) inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 14(3)(d)(iii)(dd); 2020 c. 1, Sch. 5 para. 1(1)
3. The fees for the official recognition of a test facility or organisation [F31by a United Kingdom competent authority] are in accordance with the following table(1).
Item | Activity | Fee (£) |
---|---|---|
1 | Initial official recognition of the test facility | 2,080 |
2 | Renewal of an official recognition | 2,080 |
3 | Each re-inspection | 1,560 |
Notes
(1) Article 29(3) of Regulation 1107/2009 requires that compliance with certain authorisation requirements is established by official or officially recognised tests and analyses.
Textual Amendments
F31Words in Sch. 1 para. 3 inserted (31.12.2020) by S.I. 2019/720, Sch. 1 para. 14(3A) (as inserted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 10(5))
F324. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .]
Textual Amendments
Regulation 4(2)
Textual Amendments
F33Sch. 2 substituted (6.4.2016) by The Plant Protection Products (Fees and Charges) (Amendment) Regulations 2016 (S.I. 2016/254), regs. 1, 2(3)
F34Words in Sch. 2 heading substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 15(2); 2020 c. 1, Sch. 5 para. 1(1)
[F361.] [F37Fees chargeable by a Great Britain competent authority for import tolerances] are in accordance with the following table.
Item | Category | Fee(£) |
---|---|---|
[F38A1 | Preliminary consideration of an application to determine whether the application can proceed further | 229 |
A2 | Co-ordination of applications | 1,872] |
1 | Full Human health description(1) | 16,224 |
2 | Metabolism and residues evaluation(2) | 6,760 |
3 | Residues evaluation(3) | 2,028 |
Notes
(1) [F39This category is mainly for active substances not currently approved in respect of the part of Great Britain to which the application relates. In certain cases it may also include active substances still being reviewed if toxicological endpoints have not yet been agreed and accepted in respect of that part of Great Britain.]
(2) This category is for [F40active substances] where toxicological endpoints have already been agreed [F41and accepted in respect of the part of Great Britain to which the application relates], but the residue definition has only been established for crop groups unrelated to the intended use or imported produce.
(3) This category is for [F42active substances] where relevant toxicological endpoints and residue definition have already been agreed [F43and accepted in respect of the part of Great Britain to which the application relates].
[F44Fees for multiple import tolerances for the same active substance are calculated on a modular basis with a charge applied for each crop.]]
Textual Amendments
F35Sch. 2 para. 1 heading inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 15(3); 2020 c. 1, Sch. 5 para. 1(1)
F36Sch. 2 para. 1: Sch. 2 renumbered as Sch. 2 para. 1 (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 15(4); 2020 c. 1, Sch. 5 para. 1(1)
F37Words in Sch. 2 para. 1 substituted (31.12.2020) by S.I. 2019/720, Sch. 1 para. 15(5)(a) (as substituted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(a))
F38Sch. 2 para. 1 Table Item A1, A2 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 15(5)(b); 2020 c. 1, Sch. 5 para. 1(1)
F39Sch. 2 para. 1 Note 1 substituted by S.I. 2019/720, Sch. 1 para. 15(5)(c)(i) (31.12.2020) (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(i))
F40Words in Sch. 2 para. 1 Note 2 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 15(5)(c)(ii)(aa); 2020 c. 1, Sch. 5 para. 1(1)
F41Words in Sch. 2 para. 1 Note 2 substituted (31.12.2020) by S.I. 2019/720, reg. 1(2), Sch. 1 para. 15(5)(c)(ii)(bb) (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(ii)); 2020 c. 1, Sch. 5 para. 1(1)
F42Words in Sch. 2 para. 1 Note 3 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), Sch. 1 para. 15(5)(c)(iii)(aa); 2020 c. 1, Sch. 5 para. 1(1)
F43Words in Sch. 2 para. 1 Note 3 substituted (31.12.2020) by S.I. 2019/720, reg. 1(2), Sch. 1 para. 15(5)(c)(iii)(bb) (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(ii)); 2020 c. 1, Sch. 5 para. 1(1)
2. Fees chargeable by a Great Britain competent authority for standalone MRL applications are in accordance with the following table.
Item | Category | Fee (£) |
---|---|---|
1 | Preliminary consideration of an application to determine whether the application can proceed further | 229 |
2 | Co-ordination of applications | 1,872 |
3 | Full human health description(1) | 16,224 |
4 | Metabolism and residues evaluation(2) | 6,760 |
5 | Residues evaluation(3) | 2,028 |
Notes
(1) This category is mainly for active substances not currently approved in respect of the part of Great Britain to which the application relates. In certain cases it may also include active substances still being reviewed if toxicological endpoints have not yet been agreed and accepted in respect of that part of Great Britain.
(2) This category is for active substances where toxicological endpoints have already been agreed and accepted in respect of the part of Great Britain to which the application relates but the residue definition has only been established for crop groups unrelated to the intended use.
(3) This category is for active substances where relevant toxicological endpoints and residue definition have already been agreed and accepted in respect of the part of Great Britain to which the application relates.
Fees for multiple standalone applications for the same active substance are calculated on a modular basis with a charge applied for each crop or combination of maximum residue levels.]
Textual Amendments
F45Sch. 2 para. 2 inserted (31.12.2020) by S.I. 2019/720, reg. 1(2), Sch. 1 para. 15(6) (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(3)(a)(b)); 2020 c. 1, Sch. 5 para. 1(1)
Regulation 4(2A)
Textual Amendments
Fees chargeable by a Great Britain competent authority for the evaluation of supplementary information provided in accordance with Article 14(3) of the MRL Regulation are in accordance with the following table.
Item | Category | Fee (£) |
---|---|---|
1 | Preliminary consideration of application to determine whether the application can proceed further | 229 |
2 | Co-ordination of applications | 1,872 |
3 | Simple reasoned case(1) | 416 |
4 | Analytical method(2) | 416 |
5 | Toxicology(3) | 3,120 |
6 | Metabolism and residues evaluation(4) | 6,760 |
7 | Residues evaluation(5) | 2,028 |
Notes
(1) This category is for an MRL supplementary information requirement to provide additional information on aspects of the data already evaluated or to provide evidence of the commercial availability of standards for MRL compliance.
(2) This category is for an MRL supplementary information requirement to provide an analytical method for MRL compliance.
(3) This category is for an MRL supplementary information requirement to address the toxicological relevance of a metabolite identified in plants or products of animal origin.
(4) This category is for an MRL supplementary information requirement to address plant or livestock metabolism or any other nature of residue study.
(5) This category is for an MRL supplementary information requirement to provide additional residue trials or any other magnitude of residue study including monitoring data.
Fees for multiple submissions to address MRL supplementary information for the same active substance are calculated on a modular basis with a charge applied for each MRL supplementary information requirement. Large or novel studies to address MRL supplementary information requirements will incur an additional fee, as a multiple of the original fee, if significant extra work is required over and above the usual level for the module in question.]
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Pwynt Penodol mewn Amser: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Mae Memoranda Esboniadol yn nodi datganiad byr o ddiben Offeryn Statudol ac yn rhoi gwybodaeth am ei amcan polisi a goblygiadau polisi. Maent yn ceisio gwneud yr Offeryn Statudol yn hygyrch i ddarllenwyr nad oes ganddynt gymhwyster cyfreithiol, ac maent yn cyd-fynd ag unrhyw Offeryn Statudol neu Offeryn Statudol Drafft a gyflwynwyd ger bron y Senedd o Fehefin 2004 ymlaen.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys